American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Jan 2016
Randomized Controlled Trial Multicenter StudyIntra-tracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia.
Bronchopulmonary dysplasia (BPD) is an important complication of mechanical ventilation in preterm infants, and no definite therapy can eliminate this complication. Pulmonary inflammation plays a crucial role in its pathogenesis, and glucocorticoid is one potential therapy to prevent BPD. ⋯ In very-low-birth-weight infants with severe respiratory distress syndrome, intratracheal administration of surfactant/budesonide compared with surfactant alone significantly decreased the incidence of BPD or death without immediate adverse effect. Clinical trial registered with www.clinicaltrials.gov (NCT-00883532).
-
Am. J. Respir. Crit. Care Med. · Jan 2016
PGI2 Signaling Inhibits Group 2 Innate Lymphoid Cell Responses.
Group 2 innate lymphoid cells (ILC2s) robustly produce IL-5 and IL-13, cytokines central to the asthma phenotype; however, the effect of prostaglandin (PG) I2 on ILC2 function is unknown. ⋯ These results suggest that PGI2 may be a potential therapy to reduce the ILC2 response to protease-containing aeroallergens, such as Alternaria.